Successful Closing of Precision Micro Devices (PMD) Acquisition

Jyllinge, Denmark, June 3, 2010, ORIGIO a/s (OSE: ORO), a leader in Assisted Reproductive Technologies (ART), announced today the successful closing of its acquisition of Precision Micro Devices, LLC (PMD) a privately held, U.S. company based in California. The acquisition was closed according to the terms announced in the press release on May 11, 2010.

The CEO of PMD, April Dean, has in connection with the transaction joined ORIGIO Inc. as Vice President of Research and Development and received a sign-on bonus of 25,240 ORIGIO shares. Furthermore she has received 89,594 shares as co-owner of PMD. April Dean’s holding of ORIGIO shares is hereafter 114,834.

ORIGIO a/s has in connection with the transaction issued 298,648 new shares at an average share price of NOK 10.80, which has been distributed to the sellers of PMD. ORIGIO a/s has furthermore transferred 25,240 own shares to April Dean at an average share price of NOK 11.93. ORIGIO a/s has hereafter 249,504 own shares.

For further information, please contact:
Jesper Funding Andersen, CEO: +45 4073 0963 or E-mail: jfandersen@origio.com
Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or E-mail: jbrix@origio.com

About ORIGIO a/s
ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the three product families MediCult Media, Humagen Pipets and MidAtlantic Devices, that caters for the broadest range of ART requirements. ORIGIO, which is headquartered in Jyllinge, Denmark and has companies in 9 countries, is listed on the Oslo Stock Exchange (ORO). For further  information, please visit www.origio.com.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this press release will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO’s anticipated schedule. These factors, and other factors, including, but not limited to those described in ORIGIO’s most recent annual report, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time.
ORIGIO does not assume any responsibility for updating any forward-looking statements.